Accredited Investors Employee Shareholders Institutions Private Companies Who We Serve Trading and InvestingData SolutionsPrivate Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolBrowse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunitiesForge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All InsightsPrivate Market ReportsMarket InsightsBuying and Selling Pre-IPO All ReportsPrivate Market Updates Forge Investment OutlookStartup News and TrendsPrivate Market Data and AnalyticsTech IPO Calendar for 2024Private Market ExplainedBuying Pre-IPO SharesSelling Pre-IPO Shares Glossary Videos FAQsInsights About Us Leadership Investor Relations People & Culture Careers About

Engrail Therapeutics Stock

Q: How to sell Engrail Therapeutics stock?

If you hold private company shares of Engrail Therapeutics - whether as an employee or an early investor - Forge can help you sell them. 1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have. 2. Indicate your interest to sell your Engrail Therapeutics stock on our platform. 3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

www.engrail.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $195.08MM

Engrail Therapeutics is a pharmaceutical company focused on developing precision-targeted therapies striving to transform the lives of patients suffering from severe and life-limiting neurological, neuropsychiatric, and neurodevelopmental disorders. The company is seeking to leverage scientific insights into molecular mechanisms and neurocircuitry with the goal of advancing the development of novel treatments aimed at addressing unmet medical needs. Engrail Therapeutics was founded by Stephen Cunningham and Vikram Sudarsan in 2019 and is headquartered in San Diego, CA.

Buy or sell Engrail Therapeutics stockLearn more about Engrail Therapeutics IPO

OverviewFinancingsValuation

Enterprise Value

Access Engrail Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Engrail Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Engrail Therapeutics investors also invested in these private companies

Norwest Venture Partners

ICON, Vuori, Upside Foods, GoFundMe, Harness, Weka, Common, Omada Health, Calm, DataRobot

Eight Roads Ventures

Pony.ai, Insilico Medicine, Spendesk, Akulaku, Engrail Therapeutics, Enko Chem, Pelago, Canoe Intelligence, Funnel, Doceree

Longwood Fund

Engrail Therapeutics, Tome Biosciences, Be Biopharma, Photys Therapeutics

F-Prime Capital

Neo4j, Carrot, Devoted Health, Icertis, Owkin, Hone, TraceLink, Engrail Therapeutics, Ashby, Capital Rx

Ysios Capital

Engrail Therapeutics, Corwave, Neurona Therapeutics

Red Tree Venture Capital

Engrail Therapeutics, Bicara Therapeutics

Pivotal Life Sciences

Zenas BioPharma, FogPharma, Engrail Therapeutics, Obsidian Therapeutics

Forbion

Capstan Therapeutics, Engrail Therapeutics

Abrdn

Engrail Therapeutics, Endeavor BioMedicines

RiverVest Venture Partners

Engrail Therapeutics, Bluejay Therapeutics

Team

Management Team

Vikram Sudarsan Ph.D

President & Chief Executive Officer

Kimberly Vanover Ph.D

Chief Scientific Officer

Quentin McCubbin Ph.D

Chief Technical Officer

Eve Taylor Ph.D

Senior Vice President, Clinical Development

Bill Brubaker Ph.D

Senior Vice President, Nonclinical Development

Rex E. Bosen CPA

Acting Chief Financial Officer

Estibaliz Arce Ph.D

Vice President, Translational Science and Clinical Development

Camilla Gomiero

Vice President, Commercial Strategy and Business Development

Anil Vootkur PharmD

Vice President, Corporate Development

Board Members

Jasper Bos Ph.D

Forbion

Niall O'Donnell Ph.D

RiverVest Venture Partners

Stacie Weninger Ph.D

F-Prime Capital

Tiba Aynechi Ph.D

Norwest Venture Partners

Karoly Nikolich Ph.D

Pivotal bioVenture Partners

Heath Lukatch Ph.D

Red Tree Venture Capital

Peter Bisgaard

Pivotal Life Sciences

Engrail Therapeutics stock FAQs

Can you buy Engrail Therapeutics stock?

As Engrail Therapeutics is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Engrail Therapeutics, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy Engrail Therapeutics stock?

To invest in a private company like Engrail Therapeutics through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Engrail Therapeutics stock?

Yes, you may be able to sell your Engrail Therapeutics stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Engrail Therapeutics stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Engrail Therapeutics stock on our platform.
Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is Engrail Therapeutics a public company?

No, Engrail Therapeutics is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Engrail Therapeutics’ stock price?

Engrail Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Engrail Therapeutics’ private market stock price with Forge Data.

What is Engrail Therapeutics’ stock ticker symbol?

Engrail Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

The Economic Times 03/19/2024

Engrail Therapeutics raises $157 million in funding from F-Prime Capital, others

To continue developing treatment for neurodevelopment disorders, Engrail Therapeutics raised $157 million in a series B round.

Yahoo Finance 07/18/2023

Engrail Therapeutics Initiates the ENCALM Phase 2 Clinical Trial of ENX-102 in Patients with Generalized Anxiety Disorder

Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the acquisition, development, and commercialization of transformational therapies, today announced initiation of a multi-center phase 2 clinical trial, the ENCALM Trial, to evaluate the efficacy and safety of ENX-102 in patients with generalized anxiety disorder (GAD).

Browse More Insights

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.